Healthy Clinical Trial
Official title:
The Effect of Transcranial Direct Current Stimulation Intensity on Motor Performance in Healthy Adults
to investigate the effect of stimulation intensity on motor performance in healthy adults.
60 healthy subjects were randomly allocated to one of three groups: (a) 20-min of
High-Definition transcranial direct current stimulation (HD-tDCS) with an intensity of 2 mA
(HD-tDCS 2 mA); (2) 20-min of HD-tDCS with an intensity of 1.5 mA (HD-tDCS 1.5 mA); and (3)
20-min of sham HD-tDCS (HD-tDCS sham). The stimulation was administered noninvasively using
an M x N 9-channel high definition transcranial electrical current stimulator from Soterix
Medical (New York, NY). The anodal stimulation targeted the right Brodmann area 4 (primary
motor cortex) based on HD-Targets brain modelling software (Soterix Medical, New York, NY).
Tests: The non-dominant left arm was tested. The subjects performed a sequential
point-to-point movement task on the graphics tablet. Initially, the participants were
required to perform 3 sequences without errors to familiarize themselves with the setup, the
task and the sequence. Then, they performed the pre-test which consisted of two blocks of 6
sequences, i.e. 12 sequences, with a 30 s break between blocks. Two min after starting the
appropriate stimulation, they performed 2 blocks of 6 sequences (identical to the pre-test).
After finishing the tDCS stimulation, the participants performed a post-test, which was also
identical to the pre-test. The participants returned after 24 hours to perform a retention
test, which was equivalent to the pre- and post-tests. Two outcome measures were used:
movement time (s) and the reaction time (s) of the reaching movements.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
| Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
| Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
| Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
| Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
| Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
| Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
| Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
| Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
| Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
| Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
| Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
| Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
| Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
| Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
| Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
| Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
| Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |